Precision BioSciences Reports Third-Quarter 2026 Results and Business Update
The company says PBGENE-HBV will have a late-breaking oral presentation for the ELIMINATE-B trial at AASLD’s The Liver Meeting; the body truncates before providing the year.
Story updates
12:09:38 PM UTC
SquawkNews
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a bu…